Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


Rare, but Severe: Vasculitis and Checkpoint Inhibitors.

Lindner AK, Gruenbacher G, Schachtner G, Thurnher M, Pichler R.

Eur Urol Focus. 2019 May 6. pii: S2405-4569(19)30130-0. doi: 10.1016/j.euf.2019.04.014. [Epub ahead of print] Review.


Mevalonate Metabolism in Cancer Stemness and Trained Immunity.

Gruenbacher G, Thurnher M.

Front Oncol. 2018 Sep 20;8:394. doi: 10.3389/fonc.2018.00394. eCollection 2018. Review.


Mevalonate Metabolism in Immuno-Oncology.

Gruenbacher G, Thurnher M.

Front Immunol. 2017 Dec 1;8:1714. doi: 10.3389/fimmu.2017.01714. eCollection 2017. Review.


Mevalonate metabolism governs cancer immune surveillance.

Gruenbacher G, Thurnher M.

Oncoimmunology. 2017 Jul 27;6(10):e1342917. doi: 10.1080/2162402X.2017.1342917. eCollection 2017. Review.


Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer.

Pichler R, Gruenbacher G, Culig Z, Brunner A, Fuchs D, Fritz J, Gander H, Rahm A, Thurnher M.

Cancer Immunol Immunother. 2017 Apr;66(4):427-440. doi: 10.1007/s00262-016-1945-z. Epub 2016 Dec 22.


Ecto-ATPase CD39 Inactivates Isoprenoid-Derived Vγ9Vδ2 T Cell Phosphoantigens.

Gruenbacher G, Gander H, Rahm A, Idzko M, Nussbaumer O, Thurnher M.

Cell Rep. 2016 Jul 12;16(2):444-456. doi: 10.1016/j.celrep.2016.06.009. Epub 2016 Jun 23.


T lymphocyte regulation by mevalonate metabolism.

Thurnher M, Gruenbacher G.

Sci Signal. 2015 Mar 31;8(370):re4. doi: 10.1126/scisignal.2005970. Review.


Repetitive long-term hyperbaric oxygen treatment (HBOT) administered after experimental traumatic brain injury in rats induces significant remyelination and a recovery of sensorimotor function.

Kraitsy K, Uecal M, Grossauer S, Bruckmann L, Pfleger F, Ropele S, Fazekas F, Gruenbacher G, Patz S, Absenger M, Porubsky C, Smolle-Juettner F, Tezer I, Molcanyi M, Fasching U, Schaefer U.

PLoS One. 2014 May 21;9(5):e97750. doi: 10.1371/journal.pone.0097750. eCollection 2014.


Mevalonate metabolism in cancer.

Gruenbacher G, Thurnher M.

Cancer Lett. 2015 Jan 28;356(2 Pt A):192-6. doi: 10.1016/j.canlet.2014.01.013. Epub 2014 Jan 24. Review.


Stress-related and homeostatic cytokines regulate Vγ9Vδ2 T-cell surveillance of mevalonate metabolism.

Gruenbacher G, Nussbaumer O, Gander H, Steiner B, Leonhartsberger N, Thurnher M.

Oncoimmunology. 2014 Nov 14;3(8):e953410. eCollection 2014.


Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.

Nussbaumer O, Gruenbacher G, Gander H, Komuczki J, Rahm A, Thurnher M.

J Immunol. 2013 Aug 1;191(3):1346-55. doi: 10.4049/jimmunol.1300603. Epub 2013 Jun 21.


Regulation of mevalonate metabolism in cancer and immune cells.

Thurnher M, Gruenbacher G, Nussbaumer O.

Biochim Biophys Acta. 2013 Jun;1831(6):1009-15. doi: 10.1016/j.bbalip.2013.03.003. Epub 2013 Mar 21. Review.


Novel aspects of mevalonate pathway inhibitors as antitumor agents.

Thurnher M, Nussbaumer O, Gruenbacher G.

Clin Cancer Res. 2012 Jul 1;18(13):3524-31. doi: 10.1158/1078-0432.CCR-12-0489. Epub 2012 Apr 23. Review.


DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes.

Nussbaumer O, Gruenbacher G, Gander H, Thurnher M.

Blood. 2011 Sep 8;118(10):2743-51. doi: 10.1182/blood-2011-01-328526. Epub 2011 Jun 14.


IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells.

Gruenbacher G, Gander H, Nussbaumer O, Nussbaumer W, Rahm A, Thurnher M.

Cancer Res. 2010 Dec 1;70(23):9611-20. doi: 10.1158/0008-5472.CAN-10-1968. Epub 2010 Oct 14.


CD56+ human blood dendritic cells effectively promote TH1-type gammadelta T-cell responses.

Gruenbacher G, Gander H, Rahm A, Nussbaumer W, Romani N, Thurnher M.

Blood. 2009 Nov 12;114(20):4422-31. doi: 10.1182/blood-2009-06-227256. Epub 2009 Sep 17.

Supplemental Content

Loading ...
Support Center